Low Rates of Antifungal Therapeutic Drug Monitoring Among Inpatients Who Received Itraconazole, Posaconazole, or Voriconazole, United States, 2019–2021

Kaitlin Benedict; Jeremy A.W. Gold; Mitsuru Toda; George R. Thompson; Nathan P. Wiederhold; Dallas J. Smith

doi:10.1093/ofid/ofad389

Low Rates of Antifungal Therapeutic Drug Monitoring Among Inpatients Who Received Itraconazole, Posaconazole, or Voriconazole, United States, 2019–2021

Kaitlin Benedict, Jeremy A.W. Gold, Mitsuru Toda, George R. Thompson, Nathan P. Wiederhold, Dallas J. Smith

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

Antifungal therapeutic drug monitoring (TDM) is recommended for hospitalized patients receiving itraconazole, posaconazole, or voriconazole for treatment or prophylaxis. In this analysis of hospital-based data, TDM was uncommonly performed (15.8%) in a large cohort of eligible patients, suggesting missed opportunities to avoid subtherapeutic drug levels and minimize toxicity.

Original language	English (US)
Article number	ofad389
Journal	Open Forum Infectious Diseases
Volume	10
Issue number	8
DOIs	https://doi.org/10.1093/ofid/ofad389
State	Published - Aug 1 2023

Keywords

United States
drug monitoring
itraconazole
posaconazole
voriconazole

ASJC Scopus subject areas

Oncology
Infectious Diseases

Access to Document

10.1093/ofid/ofad389

Cite this

@article{9860bd28eb2340749b25d88ff79c0b24,

title = "Low Rates of Antifungal Therapeutic Drug Monitoring Among Inpatients Who Received Itraconazole, Posaconazole, or Voriconazole, United States, 2019–2021",

abstract = "Antifungal therapeutic drug monitoring (TDM) is recommended for hospitalized patients receiving itraconazole, posaconazole, or voriconazole for treatment or prophylaxis. In this analysis of hospital-based data, TDM was uncommonly performed (15.8%) in a large cohort of eligible patients, suggesting missed opportunities to avoid subtherapeutic drug levels and minimize toxicity.",

keywords = "United States, drug monitoring, itraconazole, posaconazole, voriconazole",

author = "Kaitlin Benedict and Gold, {Jeremy A.W.} and Mitsuru Toda and Thompson, {George R.} and Wiederhold, {Nathan P.} and Smith, {Dallas J.}",

year = "2023",

month = aug,

day = "1",

doi = "10.1093/ofid/ofad389",

language = "English (US)",

volume = "10",

journal = "Open Forum Infectious Diseases",

issn = "2328-8957",

publisher = "Oxford University Press",

number = "8",

}

TY - JOUR

T1 - Low Rates of Antifungal Therapeutic Drug Monitoring Among Inpatients Who Received Itraconazole, Posaconazole, or Voriconazole, United States, 2019–2021

AU - Benedict, Kaitlin

AU - Gold, Jeremy A.W.

AU - Toda, Mitsuru

AU - Thompson, George R.

AU - Wiederhold, Nathan P.

AU - Smith, Dallas J.

PY - 2023/8/1

Y1 - 2023/8/1

N2 - Antifungal therapeutic drug monitoring (TDM) is recommended for hospitalized patients receiving itraconazole, posaconazole, or voriconazole for treatment or prophylaxis. In this analysis of hospital-based data, TDM was uncommonly performed (15.8%) in a large cohort of eligible patients, suggesting missed opportunities to avoid subtherapeutic drug levels and minimize toxicity.

AB - Antifungal therapeutic drug monitoring (TDM) is recommended for hospitalized patients receiving itraconazole, posaconazole, or voriconazole for treatment or prophylaxis. In this analysis of hospital-based data, TDM was uncommonly performed (15.8%) in a large cohort of eligible patients, suggesting missed opportunities to avoid subtherapeutic drug levels and minimize toxicity.

KW - United States

KW - drug monitoring

KW - itraconazole

KW - posaconazole

KW - voriconazole

UR - http://www.scopus.com/inward/record.url?scp=85168778482&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85168778482&partnerID=8YFLogxK

U2 - 10.1093/ofid/ofad389

DO - 10.1093/ofid/ofad389

M3 - Article

C2 - 37539059

AN - SCOPUS:85168778482

SN - 2328-8957

VL - 10

JO - Open Forum Infectious Diseases

JF - Open Forum Infectious Diseases

IS - 8

M1 - ofad389

ER -

Low Rates of Antifungal Therapeutic Drug Monitoring Among Inpatients Who Received Itraconazole, Posaconazole, or Voriconazole, United States, 2019–2021

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this